The Avastin in Trabeculectomy Study
A randomised double-blinded study to assess the ability for intravitreal bevacizumab to increase the proportion of glaucoma patients with intraocular pressure at or below target following glaucoma drainage surgery.
A/Prof John Landers
100 participants
Jun 1, 2014
Interventional
Conditions
Summary
Glaucoma is a progressive disease of the optic nerve, which if undiagnosed, can lead to blindness. Surgery is often reserved for very severe cases and as such, surgical success is imperative. Our project will address this by performing a randomised double blinded assessment of the adjunctive use of intraoperative intravitreal bevacizumab (Avastin), a currently available and widely used anti-VEGF drug, on post-operative glaucoma surgery success. If this intervention is successful, the outcomes could undoubtedly influence future surgical management.
Eligibility
Inclusion Criteria1
- Those requiring a trabeculectomy or a phaco-trabeculectomy based on the judgement of the treating surgeon
Exclusion Criteria1
- Anterior segment dysgenesis, irido-corneal-endothelial syndrome, proliferative diabetic retinopathy, congenital or juvenile-onset glaucoma, traumatic glaucoma, rubeotic glaucoma, previous corneal graft surgery, previous vitrectomy surgery requiring silicone oil, any condition for which the patient is currently receiving intravitreal anti-VEGF medication. However, previous cataract or trabeculectomy surgery is not an exclusion.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A single intraoperative intravitreal injection of bevacizumab 1.25mg in 0.05ml
Locations(2)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12614000375651